Last reviewed · How we verify
Nevirapine (NVP)
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating.
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating. Used for HIV-1 infection (in combination with other antiretroviral agents), Prevention of mother-to-child transmission of HIV-1.
At a glance
| Generic name | Nevirapine (NVP) |
|---|---|
| Also known as | Viramune |
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Nevirapine binds directly to HIV reverse transcriptase and inhibits its enzymatic activity, blocking the critical step of reverse transcription. This prevents HIV from integrating into the host cell genome and establishing persistent infection. It is used as part of combination antiretroviral therapy (ART) to suppress viral replication in HIV-infected patients.
Approved indications
- HIV-1 infection (in combination with other antiretroviral agents)
- Prevention of mother-to-child transmission of HIV-1
Common side effects
- Rash
- Stevens-Johnson syndrome / Toxic epidermal necrolysis
- Hepatotoxicity / elevated liver enzymes
- Nausea
- Headache
- Fever
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Population Pharmacokinetics of Antiretroviral in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: